Sökning: WFRF:(Weibull Caroline E) >
Greater attention s...
-
Björkholm, MagnusKarolinska Institutet
(författare)
Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma : A population-based study from Sweden
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-05-23
-
WILEY,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-358265
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358265URI
-
https://doi.org/10.1111/ejh.13090DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:138555968URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: Forty percent of Hodgkin lymphoma (HL) patients are older than 50years at diagnosis, a fact which is not commonly recognized. Older patients do significantly worse than younger patients and are rarely included in clinical trials.Methods: Using data from Swedish Cancer and Lymphoma Registries, we estimated relative survival ratios (RSRs) for 7997 HL patients (diagnosed 1973-2013; 45% 50years).Results: The 1-year RSRs (95% confidence interval; CI) for males aged 45-59, 60-69, 70-80, and 81years and over, diagnosed in 2013, were 0.95 (0.91-0.97), 0.88 (0.81-0.92), 0.74 (0.63-0.81), and 0.52 (0.35-0.67), respectively. The corresponding 1-year RSRs for females were 0.97 (0.94-0.98), 0.91 (0.85-0.95), 0.82 (0.73-0.88), and 0.66 (0.50-0.77). No improvements in 1-year of 5-year relative survival from 2000 to 2013 were observed for patients aged 45-59 or 60-69 but there were modest improvements for patients aged 70years and older. Importantly, we saw no changes in the distribution of disease or patient characteristics between 2000 and 2013.Conclusions: Elderly patients constitute a large group with clearly unmet medical needs. Our findings motivate a more active approach to including elderly patients in clinical trials. Our study provides a baseline for outcome comparison after the broader introduction of targeted drugs.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Weibull, Caroline E.Karolinska Institutet
(författare)
-
Eloranta, SandraKarolinska Institutet
(författare)
-
Smedby, Karin E.Karolinska Institutet
(författare)
-
Glimelius, Ingrid,1975-Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden;Karolinska Univ Hosp Solna, Stockholm, Sweden(Swepub:uu)inggl846
(författare)
-
Dickman, Paul W.Karolinska Institutet
(författare)
-
Karolinska InstitutetExperimentell och klinisk onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Journal of Haematology: WILEY101:1, s. 106-1140902-44411600-0609
Internetlänk
Hitta via bibliotek
Till lärosätets databas